Show simple item record

dc.contributor.authorAlirol, E
dc.contributor.authorSchrumpf, D
dc.contributor.authorAmici Heradi, J
dc.contributor.authorRiedel, A
dc.contributor.authorde Patoul, C
dc.contributor.authorQuere, M
dc.contributor.authorChappuis, F
dc.date.accessioned2013-10-16T20:00:26Z
dc.date.available2013-10-16T20:00:26Z
dc.date.issued2012-11-09
dc.identifier.citationNifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. 2013, 56 (2):195-203 Clin. Infect. Dis.en_GB
dc.identifier.issn1537-6591
dc.identifier.pmid23074318
dc.identifier.doi10.1093/cid/cis886
dc.identifier.urihttp://hdl.handle.net/10144/303511
dc.descriptionTo access this article, click on "Additional Links"en_GB
dc.description.abstractExisting diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).
dc.language.isoenen
dc.publisherOxford University Pressen_GB
dc.relation.urlhttp://cid.oxfordjournals.org//cgi/reprint/56/2/195?ijkey=n6iCHos9f2/bE&keytype=ref&siteid=ciden_GB
dc.rightsArchived with thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America and Oxford University Pressen_GB
dc.titleNifurtimox-Eflornithine Combination Therapy for Second-stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congoen
dc.contributor.departmentDivision of International and Humanitarian Medicine, University Hospitals of Geneva, Switzerland. emilie.alirol@hcuge.chen_GB
dc.identifier.journalClinical Infectious Diseasesen_GB
html.description.abstractExisting diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).


This item appears in the following Collection(s)

Show simple item record